Lv3
278 积分 2022-05-12 加入
Now with oligos: antibody–oligonucleotide conjugates are the new drug modality to watch
25天前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
1个月前
已完结
CCR2/CXCR6 enhances tumor infiltration and antitumor efficacy of MSLN CAR-T cells
4个月前
已完结
Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
6个月前
已完结
Antibody-bottlebrush prodrugs pack a punch for targeted cancer therapy
7个月前
已完结
DLL3 draws two antibody–drug conjugate deals
9个月前
已完结
皖公网安备34019202002308
